Recent Updates
Recently added Catalysts
OKYO Positive Sentiment Score: 80/100

May 2023 OKYO Pharma Limited (" OKYO " or " Company ") Result of General Meeting The board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is devel

Wednesday, May 3, 2023 1 min read
Key Takeaway: OKYO Pharma Limited held a General Meeting where all resolutions were passed successfully by a significant majority. Key resolutions included share consolidation and share allotment to directors. The company aims to tackle the unmet needs in the dry eye disease market with its developing product, OK-101. This unanimous approval suggests strong backing from shareholders, reflecting confidence in the company's strategic direction.

Market Sentiment Analysis

POSITIVE FACTORS

  • All resolutions at the General Meeting were passed with a strong majority.
  • The company is addressing a significant unmet need in the multi-billion-dollar dry eye disease market with its product OK-101.
  • Successful votes indicate strong shareholder support and confidence in the company's direction.

Full Press Release Details

board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing
OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, is pleased to announce that
at the General Meeting ("GM") of the Company held earlier today all resolutions were duly passed.
result of the poll, including the proxy voting, is as follows:
For Against Discretion Withheld For + discretion
Resolution Description Votes % Votes Cast Votes % Votes Cast Votes % Votes Cast Votes Total Votes Cast (excl. Votes Withheld) Votes % Votes Cast
RES:001 SHARE CONSOLIDATION 545,538,277 99.93 375,103 0.07 32,915 0.006 60,371 545,946,295 545,571,192 99.93
RES:002 DIRECTORS TO ALLOT SHARES 545,533,344 99.92 378,836 0.07 32,915 0.006 61,571 545,945,095 545,566,259 99.93
RES:003 PRE-EMPTION RIGHTS 545,527,392 99.92 384,788 0.07 32,915 0.006 61,571 545,945,095 545,560,307 99.93
RES:004 AMENDMENT TO ARTICLES 545,327,392 99.93 375,103 0.07 32,915 0.006 71,256 545,735,410 545,360,307 99.93
information on votes:
at 2 May 2023, there were 1,658,792,349 ordinary shares in issue. Shareholders are entitled to one vote per ordinary share. Any vote
withheld is not a vote in law and so has not been included in the calculation of the proportion of votes for and against any Resolution.
resolutions were all passed on a poll, with votes cast in accordance with proxy voting instructions submitted to the Company by the relevant
deadline, together with those cast at the GM itself, and will be available on the National Storage Mechanism, https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
result of poll and proxy voting will also be available on the Company's website, www.okyopharma.com.
OKYO Pharma Limited Gary S. Jacob, Chief Executive Officer +44 (0)20 7495 2379
Investor Relations Paul Spencer +44 (0)20 7495 2379
Optiva Securities Limited (Broker) Robert Emmet +44 (0)20 3981 4173

Frequently Asked Questions

What is OKYO Pharma Limited focusing on?

OKYO Pharma Limited specializes in ophthalmology and develops OK-101 for dry eye disease.

What was the outcome of the General Meeting?

All resolutions at the General Meeting were passed successfully.

How many ordinary shares were in issue on May 2, 2023?

There were 1,658,792,349 ordinary shares in issue on that date.

Where can I find the voting results?

Voting results will be available on the National Storage Mechanism and the company's website.

Who is the CEO of OKYO Pharma Limited?

Gary S. Jacob is the Chief Executive Officer of OKYO Pharma Limited.

Tags: OKYO Viatris Investor Conferences Healthcare ophthalmology dry eye disease shareholder support bio-pharmaceutical
Last updated: May 3, 2023